Latest News

The listing below shows our latest News Items and is updated regularly.  If you wish to post a news item please select the 'Post News' button on the right.  The displayed news feed starts on 1st August 2016.  Older items can be found here.

To 'Post Your News' use the button at the top right.



Georgia Fogden-King's Articles

Exscientia Appoints Alex Snow, Founder of Oxford Innovation Sciences and Former CEO of Lansdowne Partners, as Deputy Chairman

Exscientia, the innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery, is pleased to announce the appointment of Mr Alex Snow to its Board of Directors as Deputy Chairman. He brings significant strategic development and financial experience to the board.

Immunocore’s IMCgp100 Receives Promising Innovative Medicine (PIM) Designation Under UK Early Access to Medicines Scheme (EAMS) for the Treatment of Patients with Uveal Melanoma

Immunocore Limited, the world’s leading TCR company focused on delivering first-in-class biological therapies that transform lives, today announces that it has been informed by the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) that IMCgp100 has been granted Promising Innovative Medicines (PIM) designation for the treatment of patients with metastatic uveal melanoma.

Global Business Accelerator Programme Cell and Gene Therapy - Innovate UK organising visit to Japan

The Enterprise Europe Network (EEN), in partnership with Innovate UK is organising a funded Accelerator Programme visit to Japan for innovative UK companies operating in the Cell and Gene Therapy sector.

Summit Therapeutics to Report Financial Results for the Third Quarter And Nine Months Ended 31 October 2017 On 6 December 2017

Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, will announce its financial results for the third quarter and nine months ended 31 October 2017 on 6 December 2017. About Summit Therapeutics Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc). For more information, please contact: Summit     Glyn Edwards / Richard Pye (UK office) Tel: 44 (0)1235 443 951 ...

Activate Science has been all over Europe

Activate Science, an annual event series organised by Thermo Fisher Scientific and attended by laboratory personnel across Europe, reached delegates at 28 customer sites in 2017.

Cryopreservation of Hematopoietic Stem Cells

HSC-BANKER® from AMSBIO is a new optimised GMP grade cryopreservation medium for the banking of hematopoietic stem cellsisolated from umbilical cord blood, peripheral blood and bone marrow.    

 

BioHub Birmingham® expands to meet demand for incubator space

The BioHub Birmingham®, which provides flexible laboratory space for pre-revenue life science companies, has announced its expansion to meet the growing demand for laboratory space in the Midlands.

MSD announces plan to establish UK Discovery Centre in London

MSD, known as Merck and Co., Inc., in the US and Canada, has today announced its commitment to establish a state of the art life sciences discovery research facility in London, focussed on early bioscience discovery and entrepreneurial innovation

Life sciences investment will bring 800 jobs to Manchester

German-headquartered Qiagen are one of the firms expected to expand into a campus in the city

Ipsen get £22m investment in Wrexham

Ipsen, a global biotech group, has announced a £22m investment and recruitment drive for scientists for their base in Wrexham.

Search Posts

News Policy

OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.

OBN Noticeboard

This is an impromptu noticeboard to let people know about events, other things that are happening, perhaps lab equipment for sale etc.  Just drop an email to us, team@obn.org.uk, and we will post.